Effect of Severe Trauma on PD1 and Its Legend (PD1/L1) on T Lymphocytes and Correlation With Mortality
NCT04233723 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2020-01-18
Summary
Unlike neuro-endocrine response to trauma; posttraumatic immune alterations are not easily carried out at bedside. The majority of trials were conducted in the intensive care usually hours to days post injury.
In this trial the investigators sought assess the immune responses during emergency department trauma resuscitation by looking at the biomarkers of severe injury by comparing T lymphocytes and programmed cell death molecules and its relation with mortality.
Conditions
- Trauma Patients
Interventions
- OTHER
-
peripheral blood samples
venous puncture
Sponsors & Collaborators
-
Assiut University
lead OTHER
Principal Investigators
-
Ramy R Hennis · Assiut University
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-04-01
- Primary Completion
- 2021-01-01
- Completion
- 2021-02-01
More Related Trials
-
Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer
NCT03827343 ·Status: ACTIVE_NOT_RECRUITING
-
Study of Anti-telomerase T CD4 Immunity in Melanoma
NCT02838433 ·Status: UNKNOWN ·Phase: NA
-
Immune Cell Response to Stimuli
NCT00397280 ·Status: RECRUITING
-
Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1
NCT02840058 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy Study of Regulatory T Cells in Treating Autoimmune Hepatitis
NCT02704338 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
T Cell Response in Hypersensitivity Syndrome
NCT00213447 ·Status: COMPLETED
-
A Prospective Study to Observe Adverse Effects in Patients Receiving Anti-PD1 Immunotherapy
NCT05669638 ·Status: RECRUITING
-
Combined Infusion of Cytotoxic T-Lymphocytes and Vaccination
NCT02843321 ·Status: UNKNOWN ·Phase: PHASE1
-
Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study
NCT00445913 ·Status: COMPLETED ·Phase: PHASE1
-
Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy
NCT03548571 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Dendritic Cell Based Therapy of Metastatic Breast Cancer
NCT00197925 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Effects of Systemically Administered Hydrocortisone on the Immune System in Healthy Volunteers
NCT01281995 ·Status: COMPLETED
-
Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation
NCT02779439 ·Status: UNKNOWN ·Phase: PHASE1
-
Autologous Tolerogenic Dendritic Cells (ATDC) for Highly Sensitized Kidney Transplant Recipients
NCT06852625 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Hyporesponsiveness of Natural Killer Cells and a Dysfunctional Inflammatory Response in Critically Ill Patients
NCT02565589 ·Status: COMPLETED
-
Correlates and Consequences of Increased Immune Activation in Injection Drug Users
NCT01831284 ·Status: COMPLETED
-
Functional Characterization of CD8+ T Cells After Supramaximal Exercise
NCT06484101 ·Status: COMPLETED ·Phase: NA
-
Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia
NCT04578210 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
DC Vaccination for Postremission Therapy in AML
NCT01734304 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effect of Denileukin Diftitox on Immune System in CTCL Patients
NCT00254332 ·Status: COMPLETED
-
Study of the Anti-tumoral Immune Response
NCT02854644 ·Status: COMPLETED ·Phase: NA
-
Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients
NCT01394640 ·Status: COMPLETED
-
Idiopathic CD4 Lymphocytopenia
NCT02113930 ·Status: COMPLETED
-
Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients
NCT02739412 ·Status: COMPLETED ·Phase: PHASE2
-
Polyinosinic-Polycytidylic Acid-poly-L-lysine Carboxymethylcellulose (Poly-ICLC) in Healthy Volunteers
NCT01299662 ·Status: COMPLETED ·Phase: PHASE1